Collismycin C reduces HMGB1-mediated septic responses and improves survival rate in septic mice.
Eonmi KimSae-Kwang KuSumin YangBong-Seon LeeGeum Jin KimHyukjae ChoiJong Sup BaePublished in: Journal of Asian natural products research (2019)
We examined the effects of a 2,2'-bipyridine containing natural product, collismycin C on high mobility group box 1 (HMGB1, septic mediator)-mediated septic responses and survival rate in a mouse sepsis model. Collismycin C inhibited the HMGB1 release and downregulated HMGB1-mediated inflammatory responses in human endothelial cells. Collismycin C also inhibited HMGB1-induced hyperpermeability and leukocyte migration in mice. In addition, collismycin C treatment reduced CLP-induced HMGB1 release and sepsis-related mortality and pulmonary damage in vivo. Our results indicate that collismycin C is a potential therapeutic agent for the treatment of severe vascular inflammatory diseases by inhibiting HMGB1 signaling pathway.
Keyphrases
- acute kidney injury
- endothelial cells
- high glucose
- signaling pathway
- intensive care unit
- drug induced
- oxidative stress
- pulmonary hypertension
- cardiovascular disease
- epithelial mesenchymal transition
- metabolic syndrome
- risk factors
- septic shock
- early onset
- high fat diet induced
- skeletal muscle
- replacement therapy
- peripheral blood
- insulin resistance
- induced pluripotent stem cells
- binding protein